NCT00627146View on ClinicalTrials.gov

Extension of Phase II Therapeutic Trial With a Humanized Non-Mitogenic CD3 (ChAgly CD3) Monoclonal Antibody in Recently Diagnosed Type 1 Diabetic Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG

ChAgly CD3

6 days treatment 8mg/d intravenous

DRUG

Placebo

6 days

Trial Locations (5)

1090

Universitair Ziekenhuis and Diabetes Research Center - Brussels Free University-VUB, Brussels

3000

Department of Endocrinology and Nephrology, UZ Gasthuisberg, Katholieke Universiteit Leuven -KUL, Leuven

Unknown

Universitair Ziekenhuis Antwerpen, Antwerp

Hopital Erasme, Brussels

Hopital Schwabbing, Munich

All Listed Sponsors

collaborator

KU Leuven

OTHER

collaborator

Universiteit Antwerpen

OTHER

collaborator

Erasme University Hospital

OTHER

lead

AZ-VUB

OTHER

NCT00627146 - Extension of Phase II Therapeutic Trial With a Humanized Non-Mitogenic CD3 (ChAgly CD3) Monoclonal Antibody in Recently Diagnosed Type 1 Diabetic Patients | Biotech Hunter | Biotech Hunter